Global Antiparasitic Drugs Market

Antiparasitic Drugs Comprehensive Study by Type (Anthelmintics (Benzimidazole, Ivermectin, Pyrantel), Scabicides and Pediculicides (Lindane, Benzyl Benzoate), Antiprotozoals (Chloroquine, Pyrimethamine), Others), Application (Hospitals, Specialty Clinics, Others), Route of Administration (Oral, Injectable, Topical), Indication (Giardiasis, Trichuriasis, Filariasis, Neurocysticercosis, Hydatid Disease, Pinworm Disease, Cysticercosis, Ascariasis, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2028

Antiparasitic Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Antiparasitic Drugs Market?

Antiparasitics such as anthelmintics, antiprotozoal, and other agents are used in the treatment of parasitic infectious diseases. According to estimates by the WHO in March 2020, 1.5 billion people worldwide are affected by the parasitic disease. These diseases include gastrointestinal problems, anemia, wasting, as well as cognitive and growth deficits in children and other infections. Of every 1.5 billion people who suffer from parasitic infectious diseases, 24% of the world's people are infected with ground-borne helminth infections. Some parasitic infections are life-threatening, while others can cause discomfort if you live a healthy lifestyle. Antiparasitic drugs target the parasitic agents of various infections and attack and destroy them or inhibit their growth and development. These drugs are generally effective and work well against a limited number of specific parasites within a very specific class of parasites. Antiparasitic drugs are antimicrobial drugs that contain antibiotics that target and destroy bacteria. They also include those antifungal drugs that target and destroy fungi. These drugs can hereby be administered topically, intravenously, and orally.

Highlights from Antiparasitic Drugs Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledIpca Laboratories Ltd. (India), Zydus Cadila (India), Merck KGaA (Germany), Pfizer (United States), GlaxoSmithKline Plc. (United Kingdom), Cipla Ltd. (India), Ranbaxy Laboratories (India), Novartis AG (Switzerland), Alvizia Health Care (India), Bayer AG (Germany), Roche Holding AG (Switzerland), Arbor Pharmaceuticals Inc. (United States) and Sanofi (France)


The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that European Players will contribute to the maximum growth of Global Antiparasitic Drugs market throughout the forecasted period.

Ipca Laboratories Ltd. (India), Zydus Cadila (India), Merck KGaA (Germany), Pfizer (United States), GlaxoSmithKline Plc. (United Kingdom), Cipla Ltd. (India), Ranbaxy Laboratories (India), Novartis AG (Switzerland), Alvizia Health Care (India), Bayer AG (Germany), Roche Holding AG (Switzerland), Arbor Pharmaceuticals Inc. (United States) and Sanofi (France) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are AstraZeneca plc (United Kingdom) and Alkem Laboratories Limited (India).

Antiparasitic Drugs Market Segmentation:
ScopeSub-Segments
Application / End UserHospitals, Specialty Clinics and Others
TypeAnthelmintics [Benzimidazole, Ivermectin, Pyrantel], Scabicides and Pediculicides [Lindane, Benzyl Benzoate], Antiprotozoals [Chloroquine, Pyrimethamine] and Others
Route of AdministrationOral,Injectable,Topical
IndicationGiardiasis,Trichuriasis,Filariasis,Neurocysticercosis,Hydatid Disease,Pinworm Disease,Cysticercosis,Ascariasis,Others
Distribution ChannelHospital Pharmacies,Retail Pharmacies,Online Pharmacies


On the basis of geography, the market of Antiparasitic Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Affordability of Drugs and The Rising Trend in Convenience of Direct Purchase

Market Growth Drivers:
Rising Prevalence of Parasitic Diseases Such As Chagas Disease and Increasing Novel Drug Treatment

Challenges:
Stiff Competition among Existing Players and Lack of Awareness among the Rural Population in Developing and Underdeveloped Economies

Restraints:
High Possibilities of Substance Abuse and Addiction and Complications and Severity Involved In Taking Wrong Medications Due To Misdiagnosis or Incorrect Self-Diagnosis

Opportunities:
High Adoption and Acceptance in Developing Markets and The Increasing Research and Development of Novel Treatments

Key Target Audience
Providers of Antiparasitic Drugs, Suppliers and Distributors of Antiparasitic Drugs, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others

Market Leaders & Development Strategies
In Jun 11, 2021, Ipca Laboratories acquired 13.09 per cent stake in Trophic Wellness Pvt Ltd. The company hold 52.35 per cent of the paid-up equity share capital of Trophic Wellness Pvt Ltd (TWPL). This acquisition helped company to expand its presence in antiparasitic drugs market
In April 2023, Ipca Laboratories acquired 33.38 per cent stake in Unichem Laboratories from one of its promoters for Rs 1,034.06 crore. according to agreement Ipca acquired 2,35,01,440 shares of Unichem from one of its promoters at a price of Rs 440 per share aggregating to Rs 1,034.06 crore, the companies said in a joint statement. This acquisition helped company to expand its presence in antiparasitic drugs market


Report Objectives / Segmentation Covered

By Type
  • Anthelmintics [Benzimidazole, Ivermectin, Pyrantel]
  • Scabicides and Pediculicides [Lindane, Benzyl Benzoate]
  • Antiprotozoals [Chloroquine, Pyrimethamine]
  • Others
By Application
  • Hospitals
  • Specialty Clinics
  • Others
By Route of Administration
  • Oral
  • Injectable
  • Topical

By Indication
  • Giardiasis
  • Trichuriasis
  • Filariasis
  • Neurocysticercosis
  • Hydatid Disease
  • Pinworm Disease
  • Cysticercosis
  • Ascariasis
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Parasitic Diseases Such As Chagas Disease
      • 3.2.2. Increasing Novel Drug Treatment
    • 3.3. Market Challenges
      • 3.3.1. Stiff Competition among Existing Players
      • 3.3.2. Lack of Awareness among the Rural Population in Developing and Underdeveloped Economies
    • 3.4. Market Trends
      • 3.4.1. Affordability of Drugs
      • 3.4.2. The Rising Trend in Convenience of Direct Purchase
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antiparasitic Drugs, by Type, Application, Route of Administration, Indication, Distribution Channel and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Antiparasitic Drugs (Value)
      • 5.2.1. Global Antiparasitic Drugs by: Type (Value)
        • 5.2.1.1. Anthelmintics [Benzimidazole, Ivermectin, Pyrantel]
        • 5.2.1.2. Scabicides and Pediculicides [Lindane, Benzyl Benzoate]
        • 5.2.1.3. Antiprotozoals [Chloroquine, Pyrimethamine]
        • 5.2.1.4. Others
      • 5.2.2. Global Antiparasitic Drugs by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Specialty Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Antiparasitic Drugs by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injectable
        • 5.2.3.3. Topical
      • 5.2.4. Global Antiparasitic Drugs by: Indication (Value)
        • 5.2.4.1. Giardiasis
        • 5.2.4.2. Trichuriasis
        • 5.2.4.3. Filariasis
        • 5.2.4.4. Neurocysticercosis
        • 5.2.4.5. Hydatid Disease
        • 5.2.4.6. Pinworm Disease
        • 5.2.4.7. Cysticercosis
        • 5.2.4.8. Ascariasis
        • 5.2.4.9. Others
      • 5.2.5. Global Antiparasitic Drugs by: Distribution Channel (Value)
        • 5.2.5.1. Hospital Pharmacies
        • 5.2.5.2. Retail Pharmacies
        • 5.2.5.3. Online Pharmacies
      • 5.2.6. Global Antiparasitic Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Antiparasitic Drugs (Volume)
      • 5.3.1. Global Antiparasitic Drugs by: Type (Volume)
        • 5.3.1.1. Anthelmintics [Benzimidazole, Ivermectin, Pyrantel]
        • 5.3.1.2. Scabicides and Pediculicides [Lindane, Benzyl Benzoate]
        • 5.3.1.3. Antiprotozoals [Chloroquine, Pyrimethamine]
        • 5.3.1.4. Others
      • 5.3.2. Global Antiparasitic Drugs by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Specialty Clinics
        • 5.3.2.3. Others
      • 5.3.3. Global Antiparasitic Drugs by: Route of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Injectable
        • 5.3.3.3. Topical
      • 5.3.4. Global Antiparasitic Drugs by: Indication (Volume)
        • 5.3.4.1. Giardiasis
        • 5.3.4.2. Trichuriasis
        • 5.3.4.3. Filariasis
        • 5.3.4.4. Neurocysticercosis
        • 5.3.4.5. Hydatid Disease
        • 5.3.4.6. Pinworm Disease
        • 5.3.4.7. Cysticercosis
        • 5.3.4.8. Ascariasis
        • 5.3.4.9. Others
      • 5.3.5. Global Antiparasitic Drugs by: Distribution Channel (Volume)
        • 5.3.5.1. Hospital Pharmacies
        • 5.3.5.2. Retail Pharmacies
        • 5.3.5.3. Online Pharmacies
      • 5.3.6. Global Antiparasitic Drugs Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Antiparasitic Drugs (Price)
      • 5.4.1. Global Antiparasitic Drugs by: Type (Price)
  • 6. Antiparasitic Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ipca Laboratories Ltd. (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Zydus Cadila (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck KGaA (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cipla Ltd. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ranbaxy Laboratories (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Alvizia Health Care (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bayer AG (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Roche Holding AG (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Arbor Pharmaceuticals Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Sanofi (France)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Antiparasitic Drugs Sale, by Type, Application, Route of Administration, Indication, Distribution Channel and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Antiparasitic Drugs (Value)
      • 7.2.1. Global Antiparasitic Drugs by: Type (Value)
        • 7.2.1.1. Anthelmintics [Benzimidazole, Ivermectin, Pyrantel]
        • 7.2.1.2. Scabicides and Pediculicides [Lindane, Benzyl Benzoate]
        • 7.2.1.3. Antiprotozoals [Chloroquine, Pyrimethamine]
        • 7.2.1.4. Others
      • 7.2.2. Global Antiparasitic Drugs by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Specialty Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Antiparasitic Drugs by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injectable
        • 7.2.3.3. Topical
      • 7.2.4. Global Antiparasitic Drugs by: Indication (Value)
        • 7.2.4.1. Giardiasis
        • 7.2.4.2. Trichuriasis
        • 7.2.4.3. Filariasis
        • 7.2.4.4. Neurocysticercosis
        • 7.2.4.5. Hydatid Disease
        • 7.2.4.6. Pinworm Disease
        • 7.2.4.7. Cysticercosis
        • 7.2.4.8. Ascariasis
        • 7.2.4.9. Others
      • 7.2.5. Global Antiparasitic Drugs by: Distribution Channel (Value)
        • 7.2.5.1. Hospital Pharmacies
        • 7.2.5.2. Retail Pharmacies
        • 7.2.5.3. Online Pharmacies
      • 7.2.6. Global Antiparasitic Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Antiparasitic Drugs (Volume)
      • 7.3.1. Global Antiparasitic Drugs by: Type (Volume)
        • 7.3.1.1. Anthelmintics [Benzimidazole, Ivermectin, Pyrantel]
        • 7.3.1.2. Scabicides and Pediculicides [Lindane, Benzyl Benzoate]
        • 7.3.1.3. Antiprotozoals [Chloroquine, Pyrimethamine]
        • 7.3.1.4. Others
      • 7.3.2. Global Antiparasitic Drugs by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Specialty Clinics
        • 7.3.2.3. Others
      • 7.3.3. Global Antiparasitic Drugs by: Route of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Injectable
        • 7.3.3.3. Topical
      • 7.3.4. Global Antiparasitic Drugs by: Indication (Volume)
        • 7.3.4.1. Giardiasis
        • 7.3.4.2. Trichuriasis
        • 7.3.4.3. Filariasis
        • 7.3.4.4. Neurocysticercosis
        • 7.3.4.5. Hydatid Disease
        • 7.3.4.6. Pinworm Disease
        • 7.3.4.7. Cysticercosis
        • 7.3.4.8. Ascariasis
        • 7.3.4.9. Others
      • 7.3.5. Global Antiparasitic Drugs by: Distribution Channel (Volume)
        • 7.3.5.1. Hospital Pharmacies
        • 7.3.5.2. Retail Pharmacies
        • 7.3.5.3. Online Pharmacies
      • 7.3.6. Global Antiparasitic Drugs Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Antiparasitic Drugs (Price)
      • 7.4.1. Global Antiparasitic Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antiparasitic Drugs: by Type(USD Million)
  • Table 2. Antiparasitic Drugs Anthelmintics [Benzimidazole, Ivermectin, Pyrantel] , by Region USD Million (2017-2022)
  • Table 3. Antiparasitic Drugs Scabicides and Pediculicides [Lindane, Benzyl Benzoate] , by Region USD Million (2017-2022)
  • Table 4. Antiparasitic Drugs Antiprotozoals [Chloroquine, Pyrimethamine] , by Region USD Million (2017-2022)
  • Table 5. Antiparasitic Drugs Others , by Region USD Million (2017-2022)
  • Table 6. Antiparasitic Drugs: by Application(USD Million)
  • Table 7. Antiparasitic Drugs Hospitals , by Region USD Million (2017-2022)
  • Table 8. Antiparasitic Drugs Specialty Clinics , by Region USD Million (2017-2022)
  • Table 9. Antiparasitic Drugs Others , by Region USD Million (2017-2022)
  • Table 10. Antiparasitic Drugs: by Route of Administration(USD Million)
  • Table 11. Antiparasitic Drugs Oral , by Region USD Million (2017-2022)
  • Table 12. Antiparasitic Drugs Injectable , by Region USD Million (2017-2022)
  • Table 13. Antiparasitic Drugs Topical , by Region USD Million (2017-2022)
  • Table 14. Antiparasitic Drugs: by Indication(USD Million)
  • Table 15. Antiparasitic Drugs Giardiasis , by Region USD Million (2017-2022)
  • Table 16. Antiparasitic Drugs Trichuriasis , by Region USD Million (2017-2022)
  • Table 17. Antiparasitic Drugs Filariasis , by Region USD Million (2017-2022)
  • Table 18. Antiparasitic Drugs Neurocysticercosis , by Region USD Million (2017-2022)
  • Table 19. Antiparasitic Drugs Hydatid Disease , by Region USD Million (2017-2022)
  • Table 20. Antiparasitic Drugs Pinworm Disease , by Region USD Million (2017-2022)
  • Table 21. Antiparasitic Drugs Cysticercosis , by Region USD Million (2017-2022)
  • Table 22. Antiparasitic Drugs Ascariasis , by Region USD Million (2017-2022)
  • Table 23. Antiparasitic Drugs Others , by Region USD Million (2017-2022)
  • Table 24. Antiparasitic Drugs: by Distribution Channel(USD Million)
  • Table 25. Antiparasitic Drugs Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 26. Antiparasitic Drugs Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 27. Antiparasitic Drugs Online Pharmacies , by Region USD Million (2017-2022)
  • Table 28. South America Antiparasitic Drugs, by Country USD Million (2017-2022)
  • Table 29. South America Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 30. South America Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 31. South America Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 32. South America Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 33. South America Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 34. Brazil Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 35. Brazil Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 36. Brazil Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 37. Brazil Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 38. Brazil Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 39. Argentina Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 40. Argentina Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 41. Argentina Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 42. Argentina Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 43. Argentina Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 44. Rest of South America Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 45. Rest of South America Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 46. Rest of South America Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 47. Rest of South America Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 48. Rest of South America Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 49. Asia Pacific Antiparasitic Drugs, by Country USD Million (2017-2022)
  • Table 50. Asia Pacific Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 51. Asia Pacific Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 52. Asia Pacific Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 53. Asia Pacific Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 54. Asia Pacific Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 55. China Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 56. China Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 57. China Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 58. China Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 59. China Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 60. Japan Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 61. Japan Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 62. Japan Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 63. Japan Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 64. Japan Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 65. India Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 66. India Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 67. India Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 68. India Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 69. India Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 70. South Korea Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 71. South Korea Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 72. South Korea Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 73. South Korea Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 74. South Korea Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 75. Taiwan Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 76. Taiwan Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 77. Taiwan Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 78. Taiwan Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 79. Taiwan Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 80. Australia Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 81. Australia Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 82. Australia Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 83. Australia Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 84. Australia Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 85. Rest of Asia-Pacific Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 86. Rest of Asia-Pacific Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 87. Rest of Asia-Pacific Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 88. Rest of Asia-Pacific Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 89. Rest of Asia-Pacific Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 90. Europe Antiparasitic Drugs, by Country USD Million (2017-2022)
  • Table 91. Europe Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 92. Europe Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 93. Europe Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 94. Europe Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 95. Europe Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 96. Germany Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 97. Germany Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 98. Germany Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 99. Germany Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 100. Germany Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 101. France Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 102. France Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 103. France Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 104. France Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 105. France Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 106. Italy Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 107. Italy Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 108. Italy Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 109. Italy Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 110. Italy Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 111. United Kingdom Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 112. United Kingdom Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 113. United Kingdom Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 114. United Kingdom Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 115. United Kingdom Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 116. Netherlands Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 117. Netherlands Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 118. Netherlands Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 119. Netherlands Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 120. Netherlands Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 121. Rest of Europe Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 122. Rest of Europe Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 123. Rest of Europe Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 124. Rest of Europe Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 125. Rest of Europe Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 126. MEA Antiparasitic Drugs, by Country USD Million (2017-2022)
  • Table 127. MEA Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 128. MEA Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 129. MEA Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 130. MEA Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 131. MEA Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 132. Middle East Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 133. Middle East Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 134. Middle East Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 135. Middle East Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 136. Middle East Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 137. Africa Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 138. Africa Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 139. Africa Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 140. Africa Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 141. Africa Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 142. North America Antiparasitic Drugs, by Country USD Million (2017-2022)
  • Table 143. North America Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 144. North America Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 145. North America Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 146. North America Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 147. North America Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 148. United States Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 149. United States Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 150. United States Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 151. United States Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 152. United States Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 153. Canada Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 154. Canada Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 155. Canada Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 156. Canada Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 157. Canada Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 158. Mexico Antiparasitic Drugs, by Type USD Million (2017-2022)
  • Table 159. Mexico Antiparasitic Drugs, by Application USD Million (2017-2022)
  • Table 160. Mexico Antiparasitic Drugs, by Route of Administration USD Million (2017-2022)
  • Table 161. Mexico Antiparasitic Drugs, by Indication USD Million (2017-2022)
  • Table 162. Mexico Antiparasitic Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 163. Antiparasitic Drugs Sales: by Type(K Tons)
  • Table 164. Antiparasitic Drugs Sales Anthelmintics [Benzimidazole, Ivermectin, Pyrantel] , by Region K Tons (2017-2022)
  • Table 165. Antiparasitic Drugs Sales Scabicides and Pediculicides [Lindane, Benzyl Benzoate] , by Region K Tons (2017-2022)
  • Table 166. Antiparasitic Drugs Sales Antiprotozoals [Chloroquine, Pyrimethamine] , by Region K Tons (2017-2022)
  • Table 167. Antiparasitic Drugs Sales Others , by Region K Tons (2017-2022)
  • Table 168. Antiparasitic Drugs Sales: by Application(K Tons)
  • Table 169. Antiparasitic Drugs Sales Hospitals , by Region K Tons (2017-2022)
  • Table 170. Antiparasitic Drugs Sales Specialty Clinics , by Region K Tons (2017-2022)
  • Table 171. Antiparasitic Drugs Sales Others , by Region K Tons (2017-2022)
  • Table 172. Antiparasitic Drugs Sales: by Route of Administration(K Tons)
  • Table 173. Antiparasitic Drugs Sales Oral , by Region K Tons (2017-2022)
  • Table 174. Antiparasitic Drugs Sales Injectable , by Region K Tons (2017-2022)
  • Table 175. Antiparasitic Drugs Sales Topical , by Region K Tons (2017-2022)
  • Table 176. Antiparasitic Drugs Sales: by Indication(K Tons)
  • Table 177. Antiparasitic Drugs Sales Giardiasis , by Region K Tons (2017-2022)
  • Table 178. Antiparasitic Drugs Sales Trichuriasis , by Region K Tons (2017-2022)
  • Table 179. Antiparasitic Drugs Sales Filariasis , by Region K Tons (2017-2022)
  • Table 180. Antiparasitic Drugs Sales Neurocysticercosis , by Region K Tons (2017-2022)
  • Table 181. Antiparasitic Drugs Sales Hydatid Disease , by Region K Tons (2017-2022)
  • Table 182. Antiparasitic Drugs Sales Pinworm Disease , by Region K Tons (2017-2022)
  • Table 183. Antiparasitic Drugs Sales Cysticercosis , by Region K Tons (2017-2022)
  • Table 184. Antiparasitic Drugs Sales Ascariasis , by Region K Tons (2017-2022)
  • Table 185. Antiparasitic Drugs Sales Others , by Region K Tons (2017-2022)
  • Table 186. Antiparasitic Drugs Sales: by Distribution Channel(K Tons)
  • Table 187. Antiparasitic Drugs Sales Hospital Pharmacies , by Region K Tons (2017-2022)
  • Table 188. Antiparasitic Drugs Sales Retail Pharmacies , by Region K Tons (2017-2022)
  • Table 189. Antiparasitic Drugs Sales Online Pharmacies , by Region K Tons (2017-2022)
  • Table 190. South America Antiparasitic Drugs Sales, by Country K Tons (2017-2022)
  • Table 191. South America Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 192. South America Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 193. South America Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 194. South America Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 195. South America Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 196. Brazil Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 197. Brazil Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 198. Brazil Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 199. Brazil Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 200. Brazil Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 201. Argentina Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 202. Argentina Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 203. Argentina Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 204. Argentina Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 205. Argentina Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 206. Rest of South America Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 207. Rest of South America Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 208. Rest of South America Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 209. Rest of South America Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 210. Rest of South America Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 211. Asia Pacific Antiparasitic Drugs Sales, by Country K Tons (2017-2022)
  • Table 212. Asia Pacific Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 213. Asia Pacific Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 214. Asia Pacific Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 215. Asia Pacific Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 216. Asia Pacific Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 217. China Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 218. China Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 219. China Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 220. China Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 221. China Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 222. Japan Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 223. Japan Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 224. Japan Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 225. Japan Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 226. Japan Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 227. India Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 228. India Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 229. India Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 230. India Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 231. India Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 232. South Korea Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 233. South Korea Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 234. South Korea Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 235. South Korea Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 236. South Korea Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 237. Taiwan Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 238. Taiwan Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 239. Taiwan Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 240. Taiwan Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 241. Taiwan Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 242. Australia Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 243. Australia Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 244. Australia Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 245. Australia Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 246. Australia Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 247. Rest of Asia-Pacific Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 248. Rest of Asia-Pacific Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 249. Rest of Asia-Pacific Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 250. Rest of Asia-Pacific Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 251. Rest of Asia-Pacific Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 252. Europe Antiparasitic Drugs Sales, by Country K Tons (2017-2022)
  • Table 253. Europe Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 254. Europe Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 255. Europe Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 256. Europe Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 257. Europe Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 258. Germany Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 259. Germany Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 260. Germany Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 261. Germany Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 262. Germany Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 263. France Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 264. France Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 265. France Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 266. France Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 267. France Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 268. Italy Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 269. Italy Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 270. Italy Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 271. Italy Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 272. Italy Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 273. United Kingdom Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 274. United Kingdom Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 275. United Kingdom Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 276. United Kingdom Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 277. United Kingdom Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 278. Netherlands Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 279. Netherlands Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 280. Netherlands Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 281. Netherlands Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 282. Netherlands Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 283. Rest of Europe Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 284. Rest of Europe Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 285. Rest of Europe Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 286. Rest of Europe Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 287. Rest of Europe Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 288. MEA Antiparasitic Drugs Sales, by Country K Tons (2017-2022)
  • Table 289. MEA Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 290. MEA Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 291. MEA Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 292. MEA Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 293. MEA Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 294. Middle East Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 295. Middle East Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 296. Middle East Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 297. Middle East Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 298. Middle East Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 299. Africa Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 300. Africa Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 301. Africa Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 302. Africa Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 303. Africa Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 304. North America Antiparasitic Drugs Sales, by Country K Tons (2017-2022)
  • Table 305. North America Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 306. North America Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 307. North America Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 308. North America Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 309. North America Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 310. United States Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 311. United States Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 312. United States Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 313. United States Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 314. United States Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 315. Canada Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 316. Canada Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 317. Canada Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 318. Canada Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 319. Canada Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 320. Mexico Antiparasitic Drugs Sales, by Type K Tons (2017-2022)
  • Table 321. Mexico Antiparasitic Drugs Sales, by Application K Tons (2017-2022)
  • Table 322. Mexico Antiparasitic Drugs Sales, by Route of Administration K Tons (2017-2022)
  • Table 323. Mexico Antiparasitic Drugs Sales, by Indication K Tons (2017-2022)
  • Table 324. Mexico Antiparasitic Drugs Sales, by Distribution Channel K Tons (2017-2022)
  • Table 325. Antiparasitic Drugs: by Type(USD/Units)
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Company Basic Information, Sales Area and Its Competitors
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Company Basic Information, Sales Area and Its Competitors
  • Table 331. Company Basic Information, Sales Area and Its Competitors
  • Table 332. Company Basic Information, Sales Area and Its Competitors
  • Table 333. Company Basic Information, Sales Area and Its Competitors
  • Table 334. Company Basic Information, Sales Area and Its Competitors
  • Table 335. Company Basic Information, Sales Area and Its Competitors
  • Table 336. Company Basic Information, Sales Area and Its Competitors
  • Table 337. Company Basic Information, Sales Area and Its Competitors
  • Table 338. Company Basic Information, Sales Area and Its Competitors
  • Table 339. Antiparasitic Drugs: by Type(USD Million)
  • Table 340. Antiparasitic Drugs Anthelmintics [Benzimidazole, Ivermectin, Pyrantel] , by Region USD Million (2023-2028)
  • Table 341. Antiparasitic Drugs Scabicides and Pediculicides [Lindane, Benzyl Benzoate] , by Region USD Million (2023-2028)
  • Table 342. Antiparasitic Drugs Antiprotozoals [Chloroquine, Pyrimethamine] , by Region USD Million (2023-2028)
  • Table 343. Antiparasitic Drugs Others , by Region USD Million (2023-2028)
  • Table 344. Antiparasitic Drugs: by Application(USD Million)
  • Table 345. Antiparasitic Drugs Hospitals , by Region USD Million (2023-2028)
  • Table 346. Antiparasitic Drugs Specialty Clinics , by Region USD Million (2023-2028)
  • Table 347. Antiparasitic Drugs Others , by Region USD Million (2023-2028)
  • Table 348. Antiparasitic Drugs: by Route of Administration(USD Million)
  • Table 349. Antiparasitic Drugs Oral , by Region USD Million (2023-2028)
  • Table 350. Antiparasitic Drugs Injectable , by Region USD Million (2023-2028)
  • Table 351. Antiparasitic Drugs Topical , by Region USD Million (2023-2028)
  • Table 352. Antiparasitic Drugs: by Indication(USD Million)
  • Table 353. Antiparasitic Drugs Giardiasis , by Region USD Million (2023-2028)
  • Table 354. Antiparasitic Drugs Trichuriasis , by Region USD Million (2023-2028)
  • Table 355. Antiparasitic Drugs Filariasis , by Region USD Million (2023-2028)
  • Table 356. Antiparasitic Drugs Neurocysticercosis , by Region USD Million (2023-2028)
  • Table 357. Antiparasitic Drugs Hydatid Disease , by Region USD Million (2023-2028)
  • Table 358. Antiparasitic Drugs Pinworm Disease , by Region USD Million (2023-2028)
  • Table 359. Antiparasitic Drugs Cysticercosis , by Region USD Million (2023-2028)
  • Table 360. Antiparasitic Drugs Ascariasis , by Region USD Million (2023-2028)
  • Table 361. Antiparasitic Drugs Others , by Region USD Million (2023-2028)
  • Table 362. Antiparasitic Drugs: by Distribution Channel(USD Million)
  • Table 363. Antiparasitic Drugs Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 364. Antiparasitic Drugs Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 365. Antiparasitic Drugs Online Pharmacies , by Region USD Million (2023-2028)
  • Table 366. South America Antiparasitic Drugs, by Country USD Million (2023-2028)
  • Table 367. South America Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 368. South America Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 369. South America Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 370. South America Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 371. South America Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 372. Brazil Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 373. Brazil Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 374. Brazil Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 375. Brazil Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 376. Brazil Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 377. Argentina Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 378. Argentina Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 379. Argentina Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 380. Argentina Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 381. Argentina Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 382. Rest of South America Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 383. Rest of South America Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 384. Rest of South America Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 385. Rest of South America Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 386. Rest of South America Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 387. Asia Pacific Antiparasitic Drugs, by Country USD Million (2023-2028)
  • Table 388. Asia Pacific Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 389. Asia Pacific Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 390. Asia Pacific Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 391. Asia Pacific Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 392. Asia Pacific Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 393. China Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 394. China Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 395. China Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 396. China Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 397. China Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 398. Japan Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 399. Japan Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 400. Japan Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 401. Japan Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 402. Japan Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 403. India Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 404. India Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 405. India Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 406. India Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 407. India Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 408. South Korea Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 409. South Korea Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 410. South Korea Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 411. South Korea Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 412. South Korea Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 413. Taiwan Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 414. Taiwan Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 415. Taiwan Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 416. Taiwan Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 417. Taiwan Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 418. Australia Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 419. Australia Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 420. Australia Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 421. Australia Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 422. Australia Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 423. Rest of Asia-Pacific Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 424. Rest of Asia-Pacific Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 425. Rest of Asia-Pacific Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 426. Rest of Asia-Pacific Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 427. Rest of Asia-Pacific Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 428. Europe Antiparasitic Drugs, by Country USD Million (2023-2028)
  • Table 429. Europe Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 430. Europe Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 431. Europe Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 432. Europe Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 433. Europe Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 434. Germany Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 435. Germany Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 436. Germany Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 437. Germany Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 438. Germany Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 439. France Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 440. France Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 441. France Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 442. France Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 443. France Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 444. Italy Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 445. Italy Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 446. Italy Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 447. Italy Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 448. Italy Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 449. United Kingdom Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 450. United Kingdom Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 451. United Kingdom Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 452. United Kingdom Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 453. United Kingdom Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 454. Netherlands Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 455. Netherlands Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 456. Netherlands Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 457. Netherlands Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 458. Netherlands Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 459. Rest of Europe Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 460. Rest of Europe Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 461. Rest of Europe Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 462. Rest of Europe Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 463. Rest of Europe Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 464. MEA Antiparasitic Drugs, by Country USD Million (2023-2028)
  • Table 465. MEA Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 466. MEA Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 467. MEA Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 468. MEA Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 469. MEA Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 470. Middle East Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 471. Middle East Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 472. Middle East Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 473. Middle East Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 474. Middle East Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 475. Africa Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 476. Africa Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 477. Africa Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 478. Africa Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 479. Africa Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 480. North America Antiparasitic Drugs, by Country USD Million (2023-2028)
  • Table 481. North America Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 482. North America Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 483. North America Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 484. North America Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 485. North America Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 486. United States Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 487. United States Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 488. United States Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 489. United States Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 490. United States Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 491. Canada Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 492. Canada Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 493. Canada Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 494. Canada Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 495. Canada Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 496. Mexico Antiparasitic Drugs, by Type USD Million (2023-2028)
  • Table 497. Mexico Antiparasitic Drugs, by Application USD Million (2023-2028)
  • Table 498. Mexico Antiparasitic Drugs, by Route of Administration USD Million (2023-2028)
  • Table 499. Mexico Antiparasitic Drugs, by Indication USD Million (2023-2028)
  • Table 500. Mexico Antiparasitic Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 501. Antiparasitic Drugs Sales: by Type(K Tons)
  • Table 502. Antiparasitic Drugs Sales Anthelmintics [Benzimidazole, Ivermectin, Pyrantel] , by Region K Tons (2023-2028)
  • Table 503. Antiparasitic Drugs Sales Scabicides and Pediculicides [Lindane, Benzyl Benzoate] , by Region K Tons (2023-2028)
  • Table 504. Antiparasitic Drugs Sales Antiprotozoals [Chloroquine, Pyrimethamine] , by Region K Tons (2023-2028)
  • Table 505. Antiparasitic Drugs Sales Others , by Region K Tons (2023-2028)
  • Table 506. Antiparasitic Drugs Sales: by Application(K Tons)
  • Table 507. Antiparasitic Drugs Sales Hospitals , by Region K Tons (2023-2028)
  • Table 508. Antiparasitic Drugs Sales Specialty Clinics , by Region K Tons (2023-2028)
  • Table 509. Antiparasitic Drugs Sales Others , by Region K Tons (2023-2028)
  • Table 510. Antiparasitic Drugs Sales: by Route of Administration(K Tons)
  • Table 511. Antiparasitic Drugs Sales Oral , by Region K Tons (2023-2028)
  • Table 512. Antiparasitic Drugs Sales Injectable , by Region K Tons (2023-2028)
  • Table 513. Antiparasitic Drugs Sales Topical , by Region K Tons (2023-2028)
  • Table 514. Antiparasitic Drugs Sales: by Indication(K Tons)
  • Table 515. Antiparasitic Drugs Sales Giardiasis , by Region K Tons (2023-2028)
  • Table 516. Antiparasitic Drugs Sales Trichuriasis , by Region K Tons (2023-2028)
  • Table 517. Antiparasitic Drugs Sales Filariasis , by Region K Tons (2023-2028)
  • Table 518. Antiparasitic Drugs Sales Neurocysticercosis , by Region K Tons (2023-2028)
  • Table 519. Antiparasitic Drugs Sales Hydatid Disease , by Region K Tons (2023-2028)
  • Table 520. Antiparasitic Drugs Sales Pinworm Disease , by Region K Tons (2023-2028)
  • Table 521. Antiparasitic Drugs Sales Cysticercosis , by Region K Tons (2023-2028)
  • Table 522. Antiparasitic Drugs Sales Ascariasis , by Region K Tons (2023-2028)
  • Table 523. Antiparasitic Drugs Sales Others , by Region K Tons (2023-2028)
  • Table 524. Antiparasitic Drugs Sales: by Distribution Channel(K Tons)
  • Table 525. Antiparasitic Drugs Sales Hospital Pharmacies , by Region K Tons (2023-2028)
  • Table 526. Antiparasitic Drugs Sales Retail Pharmacies , by Region K Tons (2023-2028)
  • Table 527. Antiparasitic Drugs Sales Online Pharmacies , by Region K Tons (2023-2028)
  • Table 528. South America Antiparasitic Drugs Sales, by Country K Tons (2023-2028)
  • Table 529. South America Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 530. South America Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 531. South America Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 532. South America Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 533. South America Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 534. Brazil Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 535. Brazil Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 536. Brazil Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 537. Brazil Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 538. Brazil Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 539. Argentina Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 540. Argentina Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 541. Argentina Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 542. Argentina Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 543. Argentina Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 544. Rest of South America Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 545. Rest of South America Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 546. Rest of South America Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 547. Rest of South America Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 548. Rest of South America Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 549. Asia Pacific Antiparasitic Drugs Sales, by Country K Tons (2023-2028)
  • Table 550. Asia Pacific Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 551. Asia Pacific Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 552. Asia Pacific Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 553. Asia Pacific Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 554. Asia Pacific Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 555. China Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 556. China Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 557. China Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 558. China Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 559. China Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 560. Japan Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 561. Japan Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 562. Japan Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 563. Japan Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 564. Japan Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 565. India Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 566. India Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 567. India Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 568. India Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 569. India Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 570. South Korea Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 571. South Korea Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 572. South Korea Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 573. South Korea Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 574. South Korea Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 575. Taiwan Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 576. Taiwan Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 577. Taiwan Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 578. Taiwan Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 579. Taiwan Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 580. Australia Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 581. Australia Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 582. Australia Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 583. Australia Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 584. Australia Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 585. Rest of Asia-Pacific Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 586. Rest of Asia-Pacific Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 587. Rest of Asia-Pacific Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 588. Rest of Asia-Pacific Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 589. Rest of Asia-Pacific Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 590. Europe Antiparasitic Drugs Sales, by Country K Tons (2023-2028)
  • Table 591. Europe Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 592. Europe Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 593. Europe Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 594. Europe Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 595. Europe Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 596. Germany Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 597. Germany Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 598. Germany Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 599. Germany Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 600. Germany Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 601. France Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 602. France Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 603. France Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 604. France Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 605. France Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 606. Italy Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 607. Italy Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 608. Italy Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 609. Italy Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 610. Italy Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 611. United Kingdom Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 612. United Kingdom Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 613. United Kingdom Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 614. United Kingdom Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 615. United Kingdom Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 616. Netherlands Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 617. Netherlands Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 618. Netherlands Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 619. Netherlands Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 620. Netherlands Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 621. Rest of Europe Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 622. Rest of Europe Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 623. Rest of Europe Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 624. Rest of Europe Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 625. Rest of Europe Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 626. MEA Antiparasitic Drugs Sales, by Country K Tons (2023-2028)
  • Table 627. MEA Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 628. MEA Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 629. MEA Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 630. MEA Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 631. MEA Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 632. Middle East Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 633. Middle East Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 634. Middle East Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 635. Middle East Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 636. Middle East Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 637. Africa Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 638. Africa Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 639. Africa Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 640. Africa Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 641. Africa Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 642. North America Antiparasitic Drugs Sales, by Country K Tons (2023-2028)
  • Table 643. North America Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 644. North America Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 645. North America Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 646. North America Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 647. North America Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 648. United States Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 649. United States Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 650. United States Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 651. United States Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 652. United States Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 653. Canada Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 654. Canada Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 655. Canada Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 656. Canada Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 657. Canada Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 658. Mexico Antiparasitic Drugs Sales, by Type K Tons (2023-2028)
  • Table 659. Mexico Antiparasitic Drugs Sales, by Application K Tons (2023-2028)
  • Table 660. Mexico Antiparasitic Drugs Sales, by Route of Administration K Tons (2023-2028)
  • Table 661. Mexico Antiparasitic Drugs Sales, by Indication K Tons (2023-2028)
  • Table 662. Mexico Antiparasitic Drugs Sales, by Distribution Channel K Tons (2023-2028)
  • Table 663. Antiparasitic Drugs: by Type(USD/Units)
  • Table 664. Research Programs/Design for This Report
  • Table 665. Key Data Information from Secondary Sources
  • Table 666. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antiparasitic Drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Antiparasitic Drugs: by Application USD Million (2017-2022)
  • Figure 6. Global Antiparasitic Drugs: by Route of Administration USD Million (2017-2022)
  • Figure 7. Global Antiparasitic Drugs: by Indication USD Million (2017-2022)
  • Figure 8. Global Antiparasitic Drugs: by Distribution Channel USD Million (2017-2022)
  • Figure 9. South America Antiparasitic Drugs Share (%), by Country
  • Figure 10. Asia Pacific Antiparasitic Drugs Share (%), by Country
  • Figure 11. Europe Antiparasitic Drugs Share (%), by Country
  • Figure 12. MEA Antiparasitic Drugs Share (%), by Country
  • Figure 13. North America Antiparasitic Drugs Share (%), by Country
  • Figure 14. Global Antiparasitic Drugs: by Type K Tons (2017-2022)
  • Figure 15. Global Antiparasitic Drugs: by Application K Tons (2017-2022)
  • Figure 16. Global Antiparasitic Drugs: by Route of Administration K Tons (2017-2022)
  • Figure 17. Global Antiparasitic Drugs: by Indication K Tons (2017-2022)
  • Figure 18. Global Antiparasitic Drugs: by Distribution Channel K Tons (2017-2022)
  • Figure 19. South America Antiparasitic Drugs Share (%), by Country
  • Figure 20. Asia Pacific Antiparasitic Drugs Share (%), by Country
  • Figure 21. Europe Antiparasitic Drugs Share (%), by Country
  • Figure 22. MEA Antiparasitic Drugs Share (%), by Country
  • Figure 23. North America Antiparasitic Drugs Share (%), by Country
  • Figure 24. Global Antiparasitic Drugs: by Type USD/Units (2017-2022)
  • Figure 25. Global Antiparasitic Drugs share by Players 2022 (%)
  • Figure 26. Global Antiparasitic Drugs share by Players (Top 3) 2022(%)
  • Figure 27. Global Antiparasitic Drugs share by Players (Top 5) 2022(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Ipca Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 30. Ipca Laboratories Ltd. (India) Revenue: by Geography 2022
  • Figure 31. Zydus Cadila (India) Revenue, Net Income and Gross profit
  • Figure 32. Zydus Cadila (India) Revenue: by Geography 2022
  • Figure 33. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Merck KGaA (Germany) Revenue: by Geography 2022
  • Figure 35. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer (United States) Revenue: by Geography 2022
  • Figure 37. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 39. Cipla Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 40. Cipla Ltd. (India) Revenue: by Geography 2022
  • Figure 41. Ranbaxy Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 42. Ranbaxy Laboratories (India) Revenue: by Geography 2022
  • Figure 43. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 44. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 45. Alvizia Health Care (India) Revenue, Net Income and Gross profit
  • Figure 46. Alvizia Health Care (India) Revenue: by Geography 2022
  • Figure 47. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 48. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 49. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 50. Roche Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 51. Arbor Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 52. Arbor Pharmaceuticals Inc. (United States) Revenue: by Geography 2022
  • Figure 53. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 54. Sanofi (France) Revenue: by Geography 2022
  • Figure 55. Global Antiparasitic Drugs: by Type USD Million (2023-2028)
  • Figure 56. Global Antiparasitic Drugs: by Application USD Million (2023-2028)
  • Figure 57. Global Antiparasitic Drugs: by Route of Administration USD Million (2023-2028)
  • Figure 58. Global Antiparasitic Drugs: by Indication USD Million (2023-2028)
  • Figure 59. Global Antiparasitic Drugs: by Distribution Channel USD Million (2023-2028)
  • Figure 60. South America Antiparasitic Drugs Share (%), by Country
  • Figure 61. Asia Pacific Antiparasitic Drugs Share (%), by Country
  • Figure 62. Europe Antiparasitic Drugs Share (%), by Country
  • Figure 63. MEA Antiparasitic Drugs Share (%), by Country
  • Figure 64. North America Antiparasitic Drugs Share (%), by Country
  • Figure 65. Global Antiparasitic Drugs: by Type K Tons (2023-2028)
  • Figure 66. Global Antiparasitic Drugs: by Application K Tons (2023-2028)
  • Figure 67. Global Antiparasitic Drugs: by Route of Administration K Tons (2023-2028)
  • Figure 68. Global Antiparasitic Drugs: by Indication K Tons (2023-2028)
  • Figure 69. Global Antiparasitic Drugs: by Distribution Channel K Tons (2023-2028)
  • Figure 70. South America Antiparasitic Drugs Share (%), by Country
  • Figure 71. Asia Pacific Antiparasitic Drugs Share (%), by Country
  • Figure 72. Europe Antiparasitic Drugs Share (%), by Country
  • Figure 73. MEA Antiparasitic Drugs Share (%), by Country
  • Figure 74. North America Antiparasitic Drugs Share (%), by Country
  • Figure 75. Global Antiparasitic Drugs: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Ipca Laboratories Ltd. (India)
  • Zydus Cadila (India)
  • Merck KGaA (Germany)
  • Pfizer (United States)
  • GlaxoSmithKline Plc. (United Kingdom)
  • Cipla Ltd. (India)
  • Ranbaxy Laboratories (India)
  • Novartis AG (Switzerland)
  • Alvizia Health Care (India)
  • Bayer AG (Germany)
  • Roche Holding AG (Switzerland)
  • Arbor Pharmaceuticals Inc. (United States)
  • Sanofi (France)
Additional players considered in the study are as follows:
AstraZeneca plc (United Kingdom) , Alkem Laboratories Limited (India)
Select User Access Type

Key Highlights of Report


May 2023 244 Pages 93 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antiparasitic Drugs Market Quantitative research analysis
Global Antiparasitic Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rising Prevalence of Parasitic Diseases Such As Chagas Disease " is seen as one of major growth factors of Antiparasitic Drugs Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Antiparasitic Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Antiparasitic Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Dong Quai  Comprehensive Study by Type (Liquid, Tablets, Capsules, Tinctures, Tea, Topical creams, Powders), Application (Allergies, Headache, Premenstrual syndrome, Menstrual cramps, Fibroids, Nas...
$ 3650
Thiamazole Comprehensive Study by Application (Adults, Children), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), Thyroid Hormones Type (T3, T4), Strength (5 mg, 10 ...
$ 3500
Rectocele Treatment Comprehensive Study by Treatment (Surgical (Rectocele Repair Surgery), Non-Surgical (Floor Exercise, Pessary)), Diagnosis (Physical Test, Defecography, Imaging tests, Other tests)...
$ 3450
Calcitonin Salmon Comprehensive Study by Application (Osteoporosis, Paget's Disease, Hypercalcemia), Route of Administration (Injection, Nasal Spray), Distribution Channel (Hospital Pharmacies, Retai...
$ 3350
Dihydrocodeine Comprehensive Study by Application (Cough Suppressant, Analgesic), Route of Administration (Oral, Injection) Players and Region - Global Market Outlook to 2028
$ 3500
Amitryptyline Comprehensive Study by Patient Type (Adult, Pediatric), By Strength (10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mg tablets, 100 mg tablets, 150 mg tablets), Distribution Channel (H...
$ 3650